Avalon, GSK launch ALS company Iron Horse

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched build-to-buy company Iron Horse Therapeutics (San Diego, Calif.) with up to $10 million in series A funding and R&D support. The company is developing small molecule inhibitors of EPH receptor A4 ( EPHA4) to treat amyotrophic lateral sclerosis (ALS).

Iron Horse has an exclusive license to the inhibitors from Sanford Burnham Prebys Medical Discovery Institute (La Jolla, Calif.). The company will be housed at Avalon's COI Pharmaceuticals incubator. ...